DUBLIN , Feb. 22, 2016 /CNW/ -- Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (ENDP) (ENL.TO), today announced the availability of BELBUCA™ (buprenorphine) buccal film, the first ...

New treatment option combines proven efficacy and established safety profile of buprenorphine with a novel delivery system that adds convenience and flexibility Endo Pharmaceuticals Inc., a subsidiary ...

RALEIGH, N.C., Jan. 15, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic ...

"These posters include important scientific data for healthcare professionals to consider concerning the safety profile of buprenorphine buccal film and oxycodone," said Thomas Smith, MD, Chief ...

A new medication for chronic pain has been approved in the United States, a buprenorphine buccal film product, trade name: Belbuca. It is indicated for the treatment of chronic pain severe enough to ...

More Than 115 Million Lives Now Have Preferred Access To BELBUCA In The U.S. RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing ...

RALEIGH, N.C., June 21, 2017/PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has signed an agreement with CVS/Caremark extending access to both BELBUCA ® ...

BDSI and Belbuca are part of the solution to the opioid epidemic, not the problem. Buprenorphine is finally getting the recognition by doctors and insurance companies for being a safer long-term pain ...

Oral Presentation of Data from Phase I Safety Study & Secondary Respiratory Outcomes Comparing BELBUCA ® to Oxycodone on January 16 from 1:10pm – 2:10pm CT RALEIGH, N.C., Jan. 15, 2021 (GLOBE NEWSWIRE ...